Across much of the developing world, the promise of “leapfrogging” has always sounded both exciting and slightly out of reach. Exciting, because new technologies can sometimes bypass the slow, expensive build-out that earlier generations of countries had to endure. Out of reach, because leapfrogging is rarely just about adopting a tool—it’s about building the ecosystem around it: data systems, talent pipelines, regulatory capacity, procurement models, and the ability to turn experiments into scalable services.
Artificial intelligence is increasingly being framed as one of the missing links in that ecosystem. Not because AI is magic, but because it compresses time. It can help governments and institutions make sense of messy information faster, prioritize where to invest, and translate raw signals into decisions. When paired with “sequencing”—the ability to read biological (and increasingly other) sequences—AI becomes more than an analytics layer. It can become the engine that helps countries move from collecting data to generating usable knowledge, from research outputs to health and industrial applications, and from pilots to national capability.
For Africa in particular, sequencing is emerging as a strategic opportunity. The continent has a growing population, rising research activity, expanding clinical networks, and a fast-growing digital sector. But it also faces constraints that have historically limited participation in high-end biomedical innovation: uneven laboratory infrastructure, limited access to advanced computational resources, and gaps in training for genomics and bioinformatics. The argument now is that AI can help close some of those gaps—especially if sequencing is treated not as a standalone technology purchase, but as a capability platform.
The core idea behind leapfrogging is straightforward: instead of building every component from scratch in the same order as earlier economies, countries can adopt newer architectures and workflows that are already optimized by global experience. In telecommunications, that meant mobile networks rather than landlines. In finance, it meant digital payments rather than branch-heavy banking. In health, it can mean moving directly toward data-driven diagnostics and research systems rather than relying solely on legacy approaches.
Sequencing sits at the center of this shift because it produces a kind of information that is both powerful and underutilized. A genome sequence, for example, is not just a list of letters; it is a structured dataset that can be mined for disease risk, drug response patterns, pathogen evolution, and population-level insights. Yet the value of sequencing depends on what happens after the reads are generated. Raw sequencing data is complex, noisy, and expensive to interpret. That is where AI enters—not as a replacement for scientists, but as a multiplier for their capacity.
AI can accelerate several steps that traditionally slow down genomics work. First, it can improve quality control and error detection in sequencing pipelines, helping labs identify when data is unreliable before it contaminates downstream analyses. Second, it can automate parts of variant calling and interpretation, reducing the bottleneck created by limited numbers of trained bioinformaticians. Third, it can support phenotype-to-genotype mapping—linking genetic variants to observable traits or clinical outcomes—by learning patterns across large datasets. Fourth, it can help design experiments and prioritize which hypotheses to test next, turning genomics from a “data generation” activity into a “knowledge production” process.
But the most important leapfrog effect may be organizational rather than technical. Sequencing programs often fail not because the technology doesn’t work, but because the system around it is incomplete. Data governance is weak. Consent processes are unclear. Clinical integration is missing. Results don’t feed back into care pathways. AI can help, but only if institutions treat sequencing as part of a broader national strategy for health data, research infrastructure, and workforce development.
Consider the difference between sequencing as a one-off project and sequencing as a capability. A one-off project might generate valuable papers, but it may not build the repeatable workflows needed for routine surveillance or clinical decision support. Capability-building means establishing standardized protocols, training teams who can run and interpret sequencing consistently, and creating computational pipelines that can be maintained locally. AI can reduce the cost of interpretation and make pipelines more robust, but it cannot substitute for governance, quality assurance, and sustained funding.
This is why the “sequencing + AI” framing matters. AI can help make sequencing more accessible by lowering the marginal cost of analysis and by enabling smaller teams to do more. Yet it also raises new responsibilities: ensuring that models are validated for local populations, that biases are identified, and that results are communicated responsibly. In genomics, where ancestry and environment can shape both disease patterns and model performance, “one-size-fits-all” AI is a risk. Leapfrogging therefore requires not only adoption, but adaptation.
Africa’s opportunity, as highlighted in the reporting, is not simply to sequence more. It is to build the ability to sequence intelligently and interpret results in ways that reflect local realities. That includes building reference datasets that represent African genetic diversity, which is currently underrepresented in many global genomic databases. It also includes integrating sequencing into public health priorities—such as infectious disease surveillance, antimicrobial resistance monitoring, and outbreak response—where speed and accuracy can save lives.
In infectious disease, the combination of sequencing and AI can be particularly compelling. Pathogens evolve quickly, and traditional surveillance methods can lag behind. Sequencing provides the raw evolutionary signal; AI can help detect meaningful changes, predict likely transmission patterns, and flag variants of concern. During outbreaks, the ability to move from sample collection to actionable insights can determine whether interventions are targeted effectively or applied too late.
Yet even here, the leapfrog story is nuanced. Sequencing for surveillance requires logistics: sample transport, cold chain management, lab throughput, and data sharing agreements. AI can help optimize scheduling, triage samples, and streamline analysis, but the operational backbone still matters. Countries that succeed will likely be those that treat sequencing as a networked service—linking clinics, labs, and data platforms—rather than as isolated laboratories competing for grants.
Another area where sequencing and AI could drive leapfrogging is in precision medicine and pharmacogenomics. Many health systems in developing countries face a double challenge: high burdens of chronic disease and limited access to advanced diagnostics. Sequencing-based approaches can, in principle, tailor treatments to genetic profiles—improving outcomes and reducing trial-and-error prescribing. AI can assist by interpreting genetic markers and predicting drug response. But precision medicine is not just about algorithms; it depends on clinical pathways, clinician training, and reimbursement models. If results cannot be acted upon, the value of sequencing diminishes.
A unique take on the leapfrog opportunity is to view sequencing and AI as a “platform for learning,” not merely a platform for diagnosis. When health systems collect genomic and clinical data over time, they can learn which interventions work best for their populations. AI can help manage the complexity of longitudinal data and identify patterns that would be difficult to detect manually. Over years, this can create a feedback loop: better data leads to better models, which leads to better care, which leads to better data.
That learning loop is also relevant beyond healthcare. Sequencing-like technologies are increasingly used in agriculture, environmental monitoring, and industrial biotechnology. While the reporting focuses on sequencing in the context of Africa’s opportunities, the underlying logic extends: AI can help interpret complex sequence data, and local capability can unlock innovations in crop resilience, soil health, and bio-manufacturing. For countries seeking economic diversification, this matters because it shifts sequencing from a research luxury to a potential driver of productivity.
Still, the biggest question is whether AI can truly “leapfrog” constraints rather than simply add another layer of complexity. The answer depends on how AI is deployed. If AI is introduced as a black-box tool without transparency, local teams may struggle to maintain it or trust its outputs. If AI is deployed as an assistive layer—supporting quality control, workflow automation, and decision support with clear validation—then it can strengthen local capacity.
There is also the question of compute and data infrastructure. Sequencing generates large datasets, and AI models require computational resources. Some countries may rely on cloud services, but that introduces concerns about cost, latency, sovereignty, and data privacy. Others may build local compute clusters, which requires capital investment and ongoing maintenance. A leapfrog approach might involve hybrid strategies: using cloud for certain tasks while building local capacity for core workflows and governance. The goal should be to avoid dependency that undermines long-term sustainability.
Workforce development is another decisive factor. Sequencing and AI require interdisciplinary skills: molecular biology, laboratory operations, statistics, machine learning, and clinical interpretation. Many countries have strong pockets of talent, but scaling requires structured training programs and career pathways. Leapfrogging here means designing education and certification models that produce practical competence quickly—while also supporting deeper expertise for long-term leadership.
Partnerships will likely play a role, but they must be structured carefully. Partnerships can provide access to equipment, training, and initial datasets. However, if partnerships are extractive—taking samples and data without building local capability—the result is not leapfrogging but dependency. The more sustainable model is co-development: shared protocols, joint governance, local ownership of data, and training that ensures continuity even when external funding cycles end.
Governance is not a side issue; it is the foundation. Genomic data is sensitive. Consent frameworks must be clear about how data will be used, stored, and shared. Privacy protections must be real, not symbolic. And governance must address the reality that AI models can inadvertently reveal information or encode biases. Responsible governance includes auditing model performance, documenting limitations, and ensuring that communities understand how their data contributes to research and care.
There is also a policy dimension: procurement and regulation. Sequencing equipment and AI tools are not just technical purchases; they require procurement standards that ensure interoperability and quality. Regulatory frameworks must be able to evaluate diagnostic claims and validate AI performance. Without these, institutions may hesitate to adopt sequencing-based diagnostics at scale, slowing the leapfrog effect.
Despite these challenges, the direction of travel is clear. The global genomics ecosystem is shifting from “collect data” to “use data.”